Quick Answer
Protagonist Therapeutics, Inc reported Cash And Cash Equivalents At Carrying Value of $128.39 million for the year ending 2025.
- Protagonist Therapeutics, Inc showed an increase of +32.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Protagonist Therapeutics, Inc's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2013 to 2025 (13 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2015: $16.71 million | Q1 2016: $28.63 million | Q2 2016: $13.77 million | Q3 2016: $96.02 million | Q1 2017: $9.52 million | Q2 2017: $10.37 million | Q3 2017: $50.40 million | Q1 2018: $69.58 million | Q2 2018: $63.86 million | Q3 2018: $87.43 million | Q1 2019: $70.08 million | Q2 2019: $71.14 million | Q3 2019: $50.20 million | Q1 2020: $60.22 million | Q2 2020: $146.24 million | Q3 2020: $83.63 million | Q1 2021: $83.00 million | Q2 2021: $192.41 million | Q3 2021: $120.54 million | Q1 2022: $98.48 million | Q2 2022: $120.24 million | Q3 2022: $152.82 million | Q1 2023: $127.69 million | Q2 2023: $235.38 million | Q3 2023: $230.53 million | Q1 2024: $172.57 million | Q2 2024: $355.64 million | Q3 2024: $131.12 million | Q1 2025: $139.65 million | Q2 2025: $168.54 million | Q3 2025: $113.71 million.
- Over the full 13 years of available data (2013 to 2025), Protagonist Therapeutics, Inc's Cash And Cash Equivalents At Carrying Value has grown by 1,417.6%.
- Historical annual values: Fiscal year 2025: $128.39 million | Fiscal year 2024: $97.25 million | Fiscal year 2023: $186.73 million | Fiscal year 2022: $125.74 million | Fiscal year 2021: $123.67 million | Fiscal year 2020: $117.36 million | Fiscal year 2019: $33.01 million | Fiscal year 2018: $82.23 million | Fiscal year 2017: $106.03 million | Fiscal year 2016: $21.08 million | Fiscal year 2015: $4.06 million | Fiscal year 2014: $9.32 million | Fiscal year 2013: $8.46 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: